初治前列腺癌中前列腺特异性膜抗原的分子标志
研究以肿瘤FOLH1 RNA丰度作为PSMA PET SUVmax的替代指标(ρ=0.41),在18个独立队列5684例肿瘤样本中验证:高PSMA肿瘤雄激素受体信号更活跃,接受雄激素剥夺治疗或原发放疗后结局更好;低PSMA肿瘤具放疗抵抗分子标志,SAKK09/10试验中高PSMA者 salvage放疗64 Gy组获益、70 Gy组效应减弱。
要点
- PSMA RNA丰度与SUVmax中度相关(ρ=0.41),可作为PET的替代指标。
- 高PSMA肿瘤雄激素受体信号更活跃,ADT治疗生化复发后癌症特异性生存更长(AHR 0.54)。
- 高PSMA肿瘤原发放疗后复发时间更长(AHR 0.50),但SAKK09/10中70 Gy组获益减弱。
核心结论
- 初治前列腺癌的PSMA水平可区分肿瘤生物学行为和治疗敏感性,结果需用PET指标验证以支持基于影像的决策。
研究设计与样本
- 首先在55例原发前列腺癌中分析PSMA PET SUVmax与肿瘤FOLH1 RNA丰度的相关性。
- 随后在两个原发肿瘤大队列中发现并验证与PSMA RNA水平相关的分子通路。
- 最后在18个独立队列共5684例肿瘤样本中验证这些关联及治疗反应。
主要发现
- PSMA RNA丰度与SUVmax中度相关(ρ=0.41)。
- 高PSMA肿瘤雄激素受体信号更活跃;生化复发接受ADT者癌症特异性生存更长(AHR 0.54 [0.34-0.87];n=174)。
- 低PSMA肿瘤具放疗抵抗分子标志;高PSMA肿瘤原发放疗后复发时间更长(AHR 0.50 [0.28-0.90];n=248)。
- SAKK09/10试验(n=224)中,高PSMA肿瘤接受挽救放疗者64 Gy组至进展时间更长(RMST +7.60 [0.05-15.16]),70 Gy组效应减弱(RMST 3.52 [-3.30至10.33])。
临床怎么用
- 作者认为PSMA水平可区分初治前列腺癌的肿瘤生物学和治疗敏感性。
- 作者指出结果需用PET指标验证以支持基于影像的治疗决策。
局限性
- 使用PSMA RNA作为PET SUVmax的替代指标。
- 作者指出结果需用PET指标验证以支持基于影像的决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: We characterized tumor prostate-specific membrane antigen (PSMA) levels as a reflection of cancer biology and treatment sensitivities for treatment-naïve prostate cancer. METHODS: We first correlated PSMA positron emission tomography (PET) maximum standardized uptake values (SUVmax) in primary prostate cancer with tumor FOLH1 (PSMA RNA abundance) to establish RNA as a proxy (n = 55). We then discovered and validated molecular pathways associated with PSMA RNA levels in two large primary tumor cohorts. We validated those associations in independent cohorts (18 total; 5684 tumor samples) to characterize the pathways and treatment responses associated with PSMA. KEY FINDINGS AND LIMITATIONS: PSMA RNA abundance correlates moderately with SUVmax (ρ = 0.41). In independent cohorts, androgen receptor signaling is more active in tumors with high PSMA. Accordingly, patients with high PSMA tumors experienced longer cancer-specific survival when managed with androgen deprivation therapy for biochemical recurrence (adjusted hazard ratio [AHR] 0.54 [0.34-0.87]; n = 174). PSMA low tumors possess molecular markers of resistance to radiotherapy. Consistent with this, patients with high PSMA tumors experience longer time to recurrence following primary radiotherapy (AHR 0.50 [0.28-0.90]; n = 248). In the SAKK09/10 trial (n = 224), patients with high PSMA tumors who were managed with salvage radiotherapy experienced longer time to progression in the 64-Gy arm (restricted mean survival time [RMST] +7.60 [0.05-15.16]), but this effect was mitigated in the 70-Gy arm (RMST 3.52 [-3.30 to 10.33]). Limitations include using PSMA RNA as a surrogate for PET SUVmax. CONCLUSIONS AND CLINICAL IMPLICATIONS: PSMA levels in treatment-naïve prostate cancer differentiate tumor biology and treatment susceptibilities. These results warrant validation using PET metrics to substantiate management decisions based on imaging.
引用
- Weiner AB, Agrawal R, Wang NK, et al. Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-naïve Prostate Cancer. Eur Urol. 2024. PMID: 39294048. doi:10.1016/j.eururo.2024.09.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。